Neue Aspekte bei der pulmonalen Hypertonie im Kindesalter – kommentierte 2022ERS/ESC-PH-Guidelines

Zusammenfassung

Lungenhochdruck im Kindesalter unterscheidet sich von dem des Erwachsenenalters insbesondere durch die spezifische Pathophysiologie der herzfehlerassoziierten pulmonalarteriellen Hypertonie, das Vorkommen von entwicklungsbedingten Lungenerkrankungen und die häufige Assoziation mit chromosomalen, genetischen und syndromalen Auffälligkeiten. Die Behandlung von Kindern mit pulmonaler Hypertonie erfordert einen auf das Kindesalter zugeschnittenen modifizierten diagnostischen Algorithmus sowie pathophysiologisch orientierte therapeutische Strategien. In den aktuellen 2022 ERS/ESC-Pulmonale Hypertonie-Leitlinien werden die spezifischen Besonderheiten des Lungenhochdrucks im Kindesalter in einem Extrakapitel hervorgehoben und in diesem Artikel vom Kreis der Autorenschaft kommentiert.

Abstract

Pulmonary hypertension (PH) in childhood differs from that of adulthood particularly in the specific pathophysiology of congenital heart disease-associated pulmonary arterial hypertension, the presence of developmental lung disease, and the frequent association with chromosomal, genetic, and syndromal abnormalities. Treatment of children with PH requires a modified diagnostic algorithm tailored to childhood, as well as pathophysiologically oriented therapeutic strategies. In the current 2022 ERS/ESC-PH guidelines, the specific features of PH in children are highlighted in its own chapter and commented on by the authorship group in this article.

Schlüsselwörter

pädiatrische pulmonale Hypertonie - pulmonalarterielle Hypertonie - angeborene Herzfehler - pädiatrische Kardiologie

Keywords

pediatric pulmonary hypertension - pulmonary arterial hypertension - congenital heart disease - pediatric cardiology

Publication History

Article published online:
14 November 2023

• Literatur

• 1 Loon R vanL, Roofthooft MT, Hillege HL. et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 2011; 124: 1755-1764
• 2 Lammers AE, Apitz C. Update from the World Symposium on Pulmonary Hypertension 2018: does the new hemodynamic definition of pediatric pulmonary hypertension have an impact on treatment strategies?. Cardiovasc Diagn Ther 2021; 11: 1048-1051
• 3 Apitz C, Abdul-Khaliq H, Albinni S. et al. Neue hämodynamische Definition der pulmonalen Hypertonie. Monatsschrift Kinderheilkunde 2020; 168: 252-256
• 4 Humbert M, Kovacs G, Hoeper MM. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43: 3618-3731
• 5 Rosenzweig EB, Abman SH, Adatia I. et al. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J 2019; 53: 1801916
• 6 Berger RM, Beghetti M, Humpl T. et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012; 379: 537-546
• 7 Abman SH, Mullen MP, Sleeper LA. et al. Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry. Eur Respir J 2021; 59: 2003337
• 8 Haarman MG, Kerstjens-Frederikse WS, Vissia-Kazemier TR. et al. The genetic epidemiology of pediatric pulmonary arterial hypertension. J Pediatr 2020; 225: 65-73.e65
• 9 Levy M, Eyries M, Szezepanski I. et al. Genetic analyses in a cohort of children with pulmonary hypertension. Eur Respir J 2016; 48: 1118-1126
• 10 Chida A, Shintani M, Yagi H. et al. Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers. Am J Cardiol 2012; 110: 586-593
• 11 Girerd B, Montani D, Eyries M. et al. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 2010; 11: 73
• 12 Beghetti M, Schulze-Neick I, Berger RM. et al. Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension). Int J Cardiol 2016; 203: 325-330
• 13 Hansmann G, Apitz C. The Need for Comprehensive Cardiac Catheterization in Children With Pulmonary Hypertension. J Am Coll Cardiol 2016; 67: 1009-1010
• 14 Apitz C, Hansmann G, Schranz D. Haemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension – the European Pediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016; 102 (Suppl. 02) ii23-ii29
• 15 Simonneau G, Montani D, Celermajer DS. et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53
• 16 Lammers AE, Apitz C, Zartner P. et al. Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension – the European Pediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016; 102 (Suppl. 02) ii1-ii13
• 17 Geiger R, Strasak A, Treml B. et al. Six-minute walk test in children and adolescents. J Pediatr 2007; 150: 395-399 399.e1-2
• 18 Ploegstra MJ, Zijlstra WMH, Douwes JM. et al. Prognostic factors in pediatric pulmonary arterial hypertension: a systematic review and meta-analysis. Int J Cardiol 2015; 184: 198-207
• 19 Zijlstra WMH, Douwes JM, Rosenzweig EB. et al. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. J Am Coll Cardiol 2014; 63: 2159-2169
• 20 McLaughlin V, Channick RN, Ghofrani HA. et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46: 405-413
• 21 Grünig E, Ohnesorge J, Benjamin N. et al. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment. Respiration 2017; 94: 26-37
• 22 Hansmann G, Koestenberger M, Alastalo TP. et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant 2019; 38: 879-901
• 23 Latus H, Delhaas T, Schranz D. et al. Treatment of pulmonary arterial hypertension in children. Nat Rev Cardiol 2015; 12: 244-254
• 24 Grady RM, Canter MW, Wan F. et al. Pulmonary-to-Systemic Arterial Shunt to Treat Children With Severe Pulmonary Hypertension. J Am Coll Cardiol 2021; 78: 468-477
• 25 Ploegstra MJ, Douwes JM, Roofthooft MT. et al. Identification of treatment goals in paediatric pulmonary arterial hypertension. Eur Respir J 2014; 44: 1616-1626
• 26 Buston KM, Wood SF.  Non-compliance amongst adolescents with asthma: listening to what they tell us about self-management. Fam Pract 2000; 17: 134-138
• 27 Arjaans S, Haarman MG, Roofthooft MTR. et al. Fate of pulmonary hypertension associated with bronchopulmonary dysplasia beyond 36 weeks postmenstrual age. Arch Dis Child Fetal Neonatal Ed 2021; 106: 45-50
• 28 Goss KN, Beshish AG, Barton GP. et al. Early pulmonary vascular disease in young adults born preterm. Am J Respir Crit Care Med 2018; 198: 1549-1558
• 29 Barst RJ, Beghetti M, Pulido T. et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation 2014; 129: 1914-1923
• 30 Barst RJ, Ivy DD, Gaitan G. et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012; 125: 324-334
• 31 Ivy D, Bonnet D, Berger R. et al. Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study. Pulm Circ 2021; 11 20458940211024955
• 32 Small D, Ferguson-Sells L, Dahdah N. et al. Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: a multiple ascending-dose study. Br J Clin Pharmacol 2019; 85: 2302-2309
• 33 Barst RJ, Ivy D, Dingemanse J. et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 372-382
• 34 Beghetti M, Haworth SG, Bonnet D. et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 2009; 68: 948-955
• 35 Berger RM, Haworth SG, Bonnet D. et al. FUTURE-2: results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J Cardiol 2016; 202: 52-58
• 36 Berger RMF, Gehin M, Beghetti M. et al. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. Br J Clin Pharmacol 2017; 83: 1734-1744
• 37 Ivy D, Beghetti M, Juaneda-Simian E. et al. A randomized study of safety and efficacy of two doses of ambrisentan to treat pulmonary arterial hypertension in pediatric patients aged 8 years up to 18 years. J Pediatr 2020; 5: 100055
• 38 Takatsuki S, Rosenzweig EB, Zuckerman W. et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol 2013; 48: 27-34
• 39 Albinni S, Pavo I, Kitzmueller E. et al. Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues – a single-centre experience. Pulm Circ 2021; 11: 2045894020979503
• 40 Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197-1208
• 41 Hopper RK, Wang Y, DeMatteo V. et al. Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension. Pulm Circ 2018; 8: 2045894018759247
• 42 Lammers AE, Hislop AA, Flynn Y. et al. Epoprostenol treatment in children with severe pulmonary hypertension. Heart 2007; 93: 739-743
• 43 Douwes JM, Zijlstra WM, Rosenzweig EB. et al. Parenteral prostanoids in pediatric pulmonary arterial hypertension: start early, dose high, combine. Ann Am Thorac Soc 2022; 19: 227-237
• 44 Tella JB, Kulik TJ, McSweeney JE. et al. Prostanoids in pediatric pulmonary hypertension: clinical response, time-to-effect, and dose-response. Pulm Circ 2020; 10: 2045894020944858
• 45 García Aguilar H, Gorenflo M, Ivy DD. et al. Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study. Pulm Circ 2022; 12: e12133